ATA188: an EBV-specific T cell allogeneic treatment for MS progression | Pascal Touchon, PRESIDENT AND CHIEF EXECUTIVE OFFICER, ATARA BIOTHERAPEUTICS INC 00:10:00

Share On Facebook Share On Twitter

With more than 30 years of global biopharmaceutical leadership experience, Pascal Touchon joined Atara Biotherapeutics as President, Chief Executive Officer and member of the Board of Directors in June 2019. Pascal has committed his career to transforming the lives of patients with serious medical conditions through pioneering science, teamwork, and a commitment to excellence.

Recent Videos